- Home
- CCEC vs AVDL Comparison
CCEC vs AVDL Comparison
Compare CCEC & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEC
- AVDL
- Stock Information
- Founded
- CCEC 2007
- AVDL 2015
- Country
- CCEC Greece
- AVDL Ireland
- Employees
- CCEC N/A
- AVDL N/A
- Industry
- CCEC Marine Transportation
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- CCEC Consumer Discretionary
- AVDL Health Care
- Exchange
- CCEC Nasdaq
- AVDL Nasdaq
- Market Cap
- CCEC 1.1B
- AVDL 963.6M
- IPO Year
- CCEC 2007
- AVDL 1996
- Fundamental
- Price
- CCEC $18.32
- AVDL $10.33
- Analyst Decision
- CCEC Buy
- AVDL Strong Buy
- Analyst Count
- CCEC 1
- AVDL 6
- Target Price
- CCEC $22.00
- AVDL $24.00
- AVG Volume (30 Days)
- CCEC 17.5K
- AVDL 1.2M
- Earning Date
- CCEC 01-31-2025
- AVDL 11-12-2024
- Dividend Yield
- CCEC 3.29%
- AVDL N/A
- EPS Growth
- CCEC N/A
- AVDL N/A
- EPS
- CCEC 0.85
- AVDL N/A
- Revenue
- CCEC $447,305,000.00
- AVDL $138,160,000.00
- Revenue This Year
- CCEC N/A
- AVDL $523.86
- Revenue Next Year
- CCEC N/A
- AVDL $70.46
- P/E Ratio
- CCEC $21.38
- AVDL N/A
- Revenue Growth
- CCEC 29.66
- AVDL 1523.50
- 52 Week Low
- CCEC $13.41
- AVDL $9.41
- 52 Week High
- CCEC $20.26
- AVDL $19.09
- Technical
- Relative Strength Index (RSI)
- CCEC N/A
- AVDL 40.75
- Support Level
- CCEC N/A
- AVDL $10.35
- Resistance Level
- CCEC N/A
- AVDL $11.15
- Average True Range (ATR)
- CCEC 0.00
- AVDL 0.57
- MACD
- CCEC 0.00
- AVDL 0.12
- Stochastic Oscillator
- CCEC 0.00
- AVDL 40.89
About CCEC Capital Clean Energy Carriers Corp. Common Share
Capital Clean Energy Carriers Corp is an international shipping company. It is the leading platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.